How Amoroso was paid
$2.2M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Other | Total |
|---|---|---|---|---|---|
| Michael AmorosoPresident, Chief Executive Officer and Director | $650,875 | $451,294 | $1,025,086 | $62,212 | $2,189,467 |
| Alex KellyChief Financial Officer | $472,525 | $222,220 | $417,060 | $22,311 | $1,134,116 |
| Dario ScimecaGeneral Counsel and Secretary | $445,875 | $193,558 | $252,000 | $20,208 | $911,641 |
What changed and why
- $2.2MCEO Michael Amoroso received total compensation of $2,189,467 in 2025, representing a decrease from $4,310,914 in 2024.
- $1MStock awards for Mr. Amoroso decreased to $1,025,086 in 2025 from $3,216,563 in the prior year.
- 115%Bonuses paid for 2025 reflected corporate goal attainment up to 115% based on clinical milestones.
- $651KBase salary for Mr. Amoroso was $650,875 for fiscal 2025.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.